Pilot comparison of extended-release and standard preparations of divalproex sodium in patients with bipolar and schizoaffective disorders.
Am J Psychiatry
; 160(7): 1348-50, 2003 Jul.
Article
em En
| MEDLINE
| ID: mdl-12832255
ABSTRACT
OBJECTIVE:
The authors compared the new extended-release and standard preparations of divalproex sodium.METHOD:
Twelve patients with DSM-IV bipolar disorder or schizoaffective disorder who were clinically stable while taking the standard form of divalproex participated in the study. These patients were given a single daily dose of the extended-release preparation of divalproex in an open 6-week trial. Clinical symptoms and adverse effects were rated weekly. Doses were adjusted to maintain steady serum valproate concentrations.RESULTS:
The medication change was associated with negligible changes in clinical status and tolerability. To maintain serum drug levels, however, 21% higher doses of the extended-release preparation were required.CONCLUSIONS:
Use of extended-release divalproex once a day was as well tolerated as the standard preparation, with no change in efficacy within 6 weeks, but the daily dose needed to maintain stable serum valproic acid concentration was 21% higher.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Transtornos Psicóticos
/
Transtorno Bipolar
/
Ácido Valproico
/
Antimaníacos
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Am J Psychiatry
Ano de publicação:
2003
Tipo de documento:
Article
País de afiliação:
Estados Unidos